Abiraterone Acetate
ZYTIGA · (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate · 17-(3-pyridyl)-5,16-androstadien-3beta-acetate · ABITATERONE ACETATE · Abiraterone Acotate · (3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate · (3)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate (Ester) · (3beta)-17-(3-pyridinyl)-Androsta-5,16-dien-3-ol acetate (ester)
식별자 및 물리적 특성
| CAS No. | 154229-18-2 |
|---|---|
| 분자식 | C26H33NO2 |
| 평균 분자량 | 391.5 g/mol |
| 단동위원소 질량 | 391.2511293 g/mol |
| SMILES | CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(c4cccnc4)=CC[C@@H]32)C1 |
| InChIKey | UVIQSJCZCSLXRZ-UBUQANBQSA-N |
| PubChem CID | 9821849 |
| ChEMBL | CHEMBL271227 |
| ChEBI | CHEBI:68639 |
| EC No. | 620-314-7 |
| DTXSID | DTXSID3049043 |
화학 및 물리적 성질
| XLogP | 5.2 |
|---|---|
| 극성 표면적 | 39.2 |
| 수소 결합 공여자 수 | 0 |
| 수소 결합 수용자 수 | 3 |
| 회전 가능 결합 수 | 3 |
| 무거운 원자 수 | 29 |
| 형식 전하 | 0 |
| 복잡도 | 739 |
| 의약품 | Pharmaceuticals -> Used in Switzerland |
| Human Drugs | FDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
| 녹는점 | 127-130°C |
| 끓는 점 | 506.7±50.0 °C(Predicted) |
| 밀도 | 1.14±0.1 g/cm3(Predicted) |
| 저장 조건 | -20°C |
| 용해도 | 클로로포름(약간 용해됨), DMSO(약간 용해됨), 메탄올(약간 용해됨) |
| pKa(산도 계수) | 5.31±0.12(Predicted) |
| 물리적 상태 | 가루 |
| 색상 | 흰색에서 베이지색 |
| InChIKey | UVIQSJCZCSLXRZ-UBUQANBQSA-N |
| SMILES | C1[C@@]2(C)C(=CC[C@]3([H])[C@]2([H])CC[C@]2(C)C(C4=CC=CN=C4)=CC[C@@]32[H])C[C@@H](OC(=O)C)C1 |
화학적 성질
Off-White Solid
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 5.1% (2 of 39) of reports.DangerH302 (74.4%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P264, P270, P273, P280, P301+P317, P318, P319, P330, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 20 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Hazard Traits - Developmental ToxicityReproductive Toxicity |
| Hazard Classes and Categories | Acute Tox. 4 (74.4%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Abiraterone acetatevMost-DILI-concern8Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| 수질 위해 등급(WGK) | 3 |
| RTECS 번호 | BV7992100 |
| 관세 코드 | 2937290000 |
| 위험 등급 | Aquatic Chronic 1Repr. 1BSTOT RE 2 |
| 저장 분류 | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
용도
개요
In April 2011, the United States FDA approved abiraterone acetate (CB7630) in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. Abiraterone acetate affects prostate, testicular, and adrenal androgens by irreversibly inhibiting both the lyase and hydroxylase activity of cytochrome P450 17A (CYP17) signaling pathways (IC50's of 2.9 and 4 nM, respectively) thereby decreasing testosterone levels.Most common serious adverse events for abiraterone acetate versus placebo included fluid retention (30.5% vs. 22.3%), hypokalemia (17.1% vs. 8.4%), hypertension (9.7% vs. 7.9%), hepatic transaminase abnormalities (10.4% vs. 8.1%), and cardiac abnormalities (13.3% vs. 10.4%).
용도
Abiraterone acetate is a novel steroidal inhibitor of human Cytochrome P450 (17α-Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.